HIV/AIDS Topics HIV Treatment Drug Advisories & Warnings
European Medicines Agency Drops Class-wide Nucleoside/Nucleotide Drug Warning
- Details
- Category: Drug Advisories & Warnings
- Published on Monday, 02 November 2015 00:00
- Written by European Medicines Agency
The European Medicines Agency recently updated its advice about lipodystrophy and lactic acidosis for people being treated for HIV, and called for modification of the warning required on all nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), as these toxicities are now known to be associated with specific drugs that are no longer widely used in high-income countries. U.S. advocates have asked the Food and Drug Administration (FDA) to make a similar change.
Atripla Label Adds Drug Interactions with Hepatitis C Protease Inhibitors Boceprevir and Telaprevir
- Details
- Category: HIV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) announced this week that the product label information for Atripla -- the HIV single-tablet regimen containing efavirenz/tenofovir/emtricitabine -- has been updated to include information about drug-drug interactions with the hepatitis C virus protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek or Incivo).
Kaletra Label Updated to Add Drug Interactions, Including Boceprevir and Telaprevir
- Details
- Category: HIV Treatment
- Published on Thursday, 24 January 2013 00:00
- Written by FDA
Product label information for the HIV protease inhibitor lopinavir/ritonavir (Kaletra) was revised to include information about several additional medications with the potential for drug-drug interactions, the U.S. Food and Drug Administration (FDA) announced last week.
Atazanavir (Reyataz) Label Update Adds Kidney Warning, Drug Interactions
- Details
- Category: HIV Treatment
- Published on Tuesday, 12 February 2013 00:00
- Written by FDA
Product label information for the HIV protease inhibitor atazanavir (brand name Reyataz) was recently revised to include new warnings about cholelithiasis or gall bladder stones and interstitial nephritis (a type of kidney inflammation), as well as interactions with several other medications, including the hepatitis C virus protease inhibitor boceprevir (Victrelis).
Statin Interactions with HIV or Hepatitis C Drugs Can Cause Muscle and Kidney Damage, FDA Warns
- Details
- Category: Drug Advisories & Warnings
- Published on Friday, 02 March 2012 00:00
- Written by Press Release
Statins, a class of drugs prescribed to lower cholesterol and reduce the risk of cardiovascular disease, can interact with certain medications used to treat HIV and hepatitis C virus (HCV) potentially leading to serious side effects, the U.S. Food and Drug Administration (FDA) warned yesterday.
Complera Label Adds Low Viral Load Restriction, Liver Toxicity Warning
- Details
- Category: HIV Treatment
- Published on Tuesday, 29 January 2013 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved revised label information for Complera, Gilead Sciences' tenofovir/emtricitabine/rilpivirine single-tablet regimen. Among the changes, the updated label clarifies that this regimen is indicated for previously untreated people with low baseline viral load, as those with higher levels were more likely to experience treatment failure in clinical trials.
Raltegravir (Isentress) Label Updated with New Side Effects Warning
- Details
- Category: Approved HIV Drugs
- Published on Friday, 04 November 2011 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) this week announced that the product information for the integrase inhibitor raltegravir (brand name Isentress) has been revised to include new warnings about potential skin reactions and other adverse events.
More Articles...
- Fluconazole (Diflucan) for Fungal Infections Can Cause Birth Defects, FDA Warns
- Some Darunavir Recalled Due to Contamination
- Enfuvirtide May Increase Pneumonia Risk
- FDA Warns of Kaletra Toxicity for Premature Infants
- FDA Warns of Unusual Femur Fractures in People Taking Bisphosphonates for Osteoporosis
- FDA Announces Preliminary Data Suggesting Heart Risk with Saquinavir (Invirase) plus Ritonavir (Norvir)
Web Design and Development by